News Conference News ESC 2025 PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy Michael O'Riordan September 01, 2025
News Conference News ESC 2025 MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide Caitlin E. Cox August 30, 2025
News Conference News ESC 2025 Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support Todd Neale August 30, 2025
News Conference News ESC 2025 Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF Michael O'Riordan August 30, 2025
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD Todd Neale September 01, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Conference News ESC 2023 Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF Todd Neale September 01, 2023
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Conference News ESC 2022 No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE Shelley Wood August 26, 2022
News Conference News ESC 2021 In HFrEF, AI Shows Promise For Predicting Beta Blocker Response Yael L. Maxwell September 03, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019